Galmed Pharmaceuticals Logo
IL0011313900
A1XFUX
GLMD

Galmed Pharmaceuticals

Kurser indlæses...

Prognose

Køb
  10
Behold
  6
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Galmed: Aramchol combined with enzalutamide leads to 3–4‑fold increased cell death in preclinical prostate cancer study

    Galmed published preclinical data showing that the combination of Aramchol with enzalutamide increased cell death by 3–4‑fold versus enzalutamide alone in a VCaP prostate cancer cell line. The interaction strengthened over time; earlier data had already shown interactions of Aramchol with docetaxel. Galmed plans to engage in talks with potential partners based on a filed patent application and to further evaluate the combination. » Mere på de.investing.com


  • Galmed: new oral film formulation of Aramchol achieves significantly higher CNS exposure

    Galmed reports that a new oral film formulation of the active substance Aramchol achieves about 150% higher systemic bioavailability and roughly 300% higher central nervous system (CNS) exposure compared with conventional oral administration. The fast‑dissolving film enables buccal/sublingual uptake, reduces first‑pass metabolism and was developed to treat dysphagia in Parkinson’s patients. Aramchol acts as an inhibitor of stearoyl‑CoA desaturase 1 and showed a dose‑dependent reduction of alpha‑synuclein aggregation in earlier in vitro data with a confirmed safety profile. Galmed views the program as partner‑ready and highlights a global Parkinson’s market of more than USD 6 billion. » Mere på de.investing.com


  • Galmed: new Aramchol‑Meglumin formulation achieves significantly higher bioavailability

    Galmed reports from a pharmacokinetic phase‑1 study that Aramchol‑Meglumin granulate in single doses shows roughly five‑fold and three‑fold higher bioavailability compared with 300 mg tablets of the free Aramchol acid. The goal is a once‑daily 400 mg dose that could replace ongoing studies using 300 mg twice daily and reduce manufacturing costs by around 50%. The company highlights improved adherence prospects and is also exploring oncological indications; according to InvestingPro the stock appears undervalued at its current valuation and has high short‑term liquidity. » Mere på de.investing.com


  • Galmed teams with Tissue Dynamics to develop human models for cardiac fibrosis

    Galmed and Tissue Dynamics have launched a collaboration to develop a human model for chronic cardiac fibrosis that combines vascularized heart organoids with embedded metabolic sensors and real‑time monitoring. The aim is to investigate Aramchol‑based therapeutic approaches and to apply Galmed’s expertise in SCD1 biology to modulate fibrotic signaling pathways. The model is intended to reproduce chronic remodeling after myocardial infarction and heart failure with preserved ejection fraction, shortcomings of existing animal models and short‑term assays. Galmed’s stock is currently trading low with a small market capitalization; investors are expecting the quarterly report on May 20. » Mere på de.investing.com


  • Galmed partners with Tel Aviv University to test Aramchol against brain metastases

    Galmed announced a research collaboration with Ramot at Tel Aviv University to evaluate Aramchol, a brain‑penetrant SCD1 inhibitor, as a targeted therapy for metastatic brain cancer. The collaboration combines genomic analyses and modeling to assess efficacy in p53‑deficient brain metastases. The announcement recently lifted the stock by 33%, but the share remains significantly down on a six‑month view. Galmed aims to advance Aramchol beyond its prior liver disease indications into oncological applications. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Galmed Pharmaceuticals en omsætning på 0 € og et nettoresultat på -2,39 mio. €
(EUR) juni 2026
YoY
Omsætning 0 -
Bruttofortjeneste 0 -
Nettoresultat -2,39 mio. 12,71 %
EBITDA -2,43 mio. 14,87 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
4,34 mio. €
Antal aktier
1,03 mio.
Højeste/laveste i 52 uger
11,98 € - 2,98 €
Udbytte Nej
Beta
0,67
P/E (PE Ratio)
-
PEG (PEG Ratio)
-
K/I (PB Ratio)
-
P/S (PS Ratio)
-

Virksomhedsprofil

Galmed Pharmaceuticals Ltd., et klinisk-stadie biofarmaceutisk selskab, fokuserer på udvikling af terapeutika til behandling af leversygdomme. Selskabet udvikler Aramchol, en oral terapi, som er i fase III-undersøgelse til behandling af non-alkoholisk steatohepatitis (NASH) hos patienter med overvægt eller fedme, og som er prædiabetiske eller har type II-diabetes mellitus. Selskabet evaluerer også Aramchol gennem ARRIVE Study, et fase IIa-klinisk forsøg med HIV-associeret non-alkoholisk fedtleversygdom og lipodystrofi. Derudover udvikler det Amilo-5MER, en syntetisk peptid bestående af 5 aminosyrer: methionin, threonin, alanin, asparaginsyre og valin. Selskabet har en forskningsaftale med Gannex Pharma Co., Ltd. om udvikling af en kombinationsbehandling af ASC41 (THR-beta-agonist) og Aramchol (SCD 1-hæmmer) til behandling af NASH; en forsknings- og udviklingssamarbejdsaftale med MyBiotics Pharma Ltd. om at identificere det udvalgte mikrobiom-repertoire, der er forbundet med responset på Aramchol; og en licensaftale med Samil Pharma. Co., Ltd. om kommercialisering af Aramchol i Republikken Korea. Galmed Pharmaceuticals Ltd. blev grundlagt i 2000 og har hovedsæde i Tel Aviv, Israel.

Navn
Galmed Pharmaceuticals
CEO
Allen Baharaff
Hjemsted Ramat Gan, ta
Israel
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
13.03.2014
Medarbejdere 6

Tickersymboler

Børs Symbol
NASDAQ
GLMD
Frankfurt
GPH.F
🍪

Parqet  bruger cookies. Læs mere